Lung Cancer

Antonio Passaro, MD, PhD, discusses testing methodologies and clinical trials for MET, the most studied resistance biomarker, following progression on EGFR TKIs.

Xiuning Le, MD, PhD, discusses efficacy data with firmonertinib for the treatment of patients with EGFR PACC–mutated NSCLC.

Xiuning Le, MD, PhD, discusses the prevalence of EGFR PACC mutations in NSCLC.

Percy Lee, MD, discusses the importance of considering radiation therapy techniques like IMRT and proton therapy for patients with locally advanced NSCLC.

Researchers developed a way to predict how lung cancer cells will respond to different therapies, allowing for more effective individualized treatment.

Panelists discuss how to pivot treatment plans when patients cannot proceed to surgery after induction therapy, emphasizing the importance of determining resectability up front and having multidisciplinary contingency plans.

Panelists discuss how resectability determination remains surgeon-dependent and institution-specific, requiring careful consideration of both technical feasibility (“can you”) and appropriateness (“should you”) for individual patients.

Leading experts across oncology specialties preview the key studies and data they are most anticipating ahead of the 2025 ESMO Congress.

Preview the top lung, breast, GI, GU, gynecologic, and hematologic oncology abstracts and topics ahead of the 2025 ESMO Congress.

Eric K. Singhi, MD, and Sandip P. Patel, MD, discuss the use of immunotherapy after prior immunotherapy for early-stage NSCLC.

Eric K. Singhi, MD, and Sandip P. Patel, MD, discuss 5-year data for cemiplimab plus chemotherapy in advanced NSCLC.

Panelists discuss how monitoring for long-term immunotherapy toxicities requires regular imaging and symptom assessment, with early recognition and treatment of pneumonitis, hypothyroidism, and adrenal insufficiency being critical for maintaining patients on therapy and preventing chronic complications.

Panelists discuss how managing toxicities during chemoradiation requires proactive counseling about esophagitis and fatigue, while immunotherapy consolidation typically doesn’t enhance these acute toxicities, making it feasible to start within the recommended timeframe after completion of chemoradiation.

Dr Bazhenova discusses the FDA approval of sunvozertinib for patients with EGFR-mutated metastatic non–small cell lung cancer.

VT3989 has received fast track designation from the FDA for unresectable malignant nonpleural or pleural mesothelioma after progression on prior therapy.

Sagus Sampath, MD, discusses the safety profile of consolidative radiotherapy administered in conjunction with osimertinib in advanced EGFR-mutant NSCLC

Julia Rotow, MD, and Jyoti Malhotra, MD, MPH, discuss the investigation of sigvotatug vedotin plus pembrolizumab in NSCLC.

Julia Rotow, MD, and Jyoti Malhotra, MD, MPH, discuss the investigation of sigvotatug vedotin in nonsquamous NSCLC.

Eric K. Singhi, MD, and Sandip P. Patel, MD, discuss the management of immune-related adverse effects in advanced NSCLC.

Eric K. Singhi, MD, and Sandip P. Patel, MD, discuss the impact of the FDA approval of cemiplimab plus chemotherapy in advanced NSCLC.

Lorlatinib has received NICE’s recommendation for untreated advanced non–small cell lung cancer.

Panelists discuss how multidisciplinary coordination and early communication between surgical, pulmonary, and oncology teams ensures adequate tissue procurement for molecular testing from the initial biopsy.

Panelists discuss how to manage the waiting period for biomarker results while balancing urgency in curable patients, emphasizing the importance of tissue-based testing over liquid biopsies in early-stage disease.

Panelists discuss how surgeon-led ultrasound-guided biopsies can expedite care timelines and overcome barriers to guideline-concordant biomarker testing that still affects one-third of eligible patients.

Check out this September recap of OncLive’s coverage of the top news and expert insights in lung cancer.